Literature DB >> 24692708

Metformin suppresses sonic hedgehog expression in pancreatic cancer cells.

Masafumi Nakamura1, Ayako Ogo, Masahiro Yamura, Yoshiyuki Yamaguchi, Hiroshi Nakashima.   

Abstract

BACKGROUND/AIM: Metformin use has previously been associated with decreased cancer risk. The Hedgehog signaling pathway is a well-characterized early and late mediator of pancreatic cancer oncogenesis. The aim of the present study was to clarify the effect of metformin on factors involved in Hedgehog signaling.
MATERIALS AND METHODS: BxPC3 human pancreatic cancer cells were treated with metformin, and Sonic hedgehog (Shh) mRNA and protein levels were examined by real time reverse transcription-polymerase chain reaction, immunohistochemistry and immunoblotting, respectively. The effect of metformin on Shh levels was also examined in three other cancer cell lines.
RESULTS: Shh protein and mRNA expression was suppressed by metformin in BxPC3 cells. This phenomenon was further confirmed in three other cancer cell lines. Shh mRNA expression was inhibited by metformin in a concentration-dependent manner in two cancer cell lines.
CONCLUSION: Metformin reduces the expression of Shh in several cancer cell lines including pancreatic cancer cell.

Entities:  

Keywords:  Hedgehog signaling pathway; Pancreatic cancer; Sonic Hedgehog; metformin

Mesh:

Substances:

Year:  2014        PMID: 24692708

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.

Authors:  G Zhou; J Yu; A Wang; S-H Liu; J Sinnett-Smith; J Wu; R Sanchez; J Nemunaitis; C Ricordi; E Rozengurt; F C Brunicardi
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

Review 2.  Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.

Authors:  Judith M Graber; Shou-En Lu; Yong Lin; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

Review 3.  The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.

Authors:  Jun Gong; Gauri Kelekar; James Shen; John Shen; Sukhpreet Kaur; Monica Mita
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

4.  Hedgehog signalling in myeloid cells impacts on body weight, adipose tissue inflammation and glucose metabolism.

Authors:  Julia Braune; Ulrike Weyer; Madlen Matz-Soja; Constance Hobusch; Matthias Kern; Anne Kunath; Nora Klöting; Susann Kralisch; Matthias Blüher; Rolf Gebhardt; Yana Zavros; Ingo Bechmann; Martin Gericke
Journal:  Diabetologia       Date:  2017-02-23       Impact factor: 10.122

5.  Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway.

Authors:  Chao Niu; Zhiwei Chen; Kyoung Tae Kim; Jia Sun; Mei Xue; Gen Chen; Santie Li; Yingjie Shen; Zhongxin Zhu; Xu Wang; Jiaojiao Liang; Chao Jiang; Weitao Cong; Litai Jin; Xiaokun Li
Journal:  Autophagy       Date:  2019-01-27       Impact factor: 16.016

Review 6.  Repurposing metformin for the treatment of gastrointestinal cancer.

Authors:  Ademar Dantas Cunha Júnior; Arinilda Campos Bragagnoli; Felipe Osório Costa; José Barreto Campello Carvalheira
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

7.  Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.

Authors:  Cong Fan; Yunshan Wang; Ziming Liu; Ying Sun; Xiuwen Wang; Guangwei Wei; Junmin Wei
Journal:  Int J Mol Med       Date:  2015-05-21       Impact factor: 4.101

Review 8.  Diabetes, pancreatic cancer, and metformin therapy.

Authors:  Jun Gong; Lori A Robbins; Aurelia Lugea; Richard T Waldron; Christie Y Jeon; Stephen J Pandol
Journal:  Front Physiol       Date:  2014-11-07       Impact factor: 4.566

Review 9.  Targeting cancer cell metabolism in pancreatic adenocarcinoma.

Authors:  Romain Cohen; Cindy Neuzillet; Annemilaï Tijeras-Raballand; Sandrine Faivre; Armand de Gramont; Eric Raymond
Journal:  Oncotarget       Date:  2015-07-10

10.  Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Authors:  Carminia Maria Della Corte; Vincenza Ciaramella; Concetta Di Mauro; Maria Domenica Castellone; Federica Papaccio; Morena Fasano; Ferdinando Carlo Sasso; Erika Martinelli; Teresa Troiani; Ferdinando De Vita; Michele Orditura; Roberto Bianco; Fortunato Ciardiello; Floriana Morgillo
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.